Pioneers in Neuroscience

BIOGEN COVID-19 INFORMATION CENTER

Thank you to the many front-line workers and organizations working tirelessly to help in these difficult days. Please find updates on Biogen’s response to COVID-19 here.

5/28/20 7:30 AM EDT
Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science
View all news
Our Stories

Biogen is pioneering an innovative network called MS PATHS (Multiple Sclerosis Partners Advancing Technology and Health Solutions), which has the potential to transform patient care by using real-world data to better track and manage disease.

2019 Year in Review

Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen in our 2019 Year in Review.

Our focus

We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience.

REGARDING ADUCANUMAB

Biogen shared Phase 3 top-line data on our investigational therapy for early Alzheimer’s disease at the 12th Clinical Trials on Alzheimer's Disease (CTAD) conference. Watch the presentation.

For investor inquiries related to this announcement, please contact Biogen Investor Relations at IR@pchubi.com.

On October 22, 2019, Biogen announced that, after consulting with the U.S. Food and Drug Administration (FDA), Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer’s disease.

Learn more.

Follow us on social media